by NYU Langone Health Credit: Unsplash/CC0 Public Domain Severe inflammation weakens the body’s ability to kill cancerous blood cells in people with acute myeloid leukemia (AML), a new study shows. Experiments in human cells also revealed how increasing levels of inflammation, marked by an aggressive reaction of immune cells in the bone marrow, altered the makeup of immune B cells...
by Queen Mary, University of London Noncoding mutations impacting BCL genes. a, Genome view of BCL2 5′ UTR. The significantly mutated region is indicated by a black rectangle. Individual somatic mutations are shown in blue. b, Gene expression of BCL2 in TPM determined by RNA-seq in samples with BCL2 5′ UTR mutations versus WT. Black dots are...
T-cell acute lymphoblastic leukemia, or T-ALL, affects more than 6,000 Americans each year. Researchers characterized the thymocyte cells—an immune cell present in the thymus—while studying mice with T-ALL. They determined all of the rodent tumors originated from the same type of T cell that expresses a unique set of molecular markers. “Once we identified the cell in...
by Melissa Rohman, Northwestern University Credit: Pixabay/CC0 Public Domain [Northwestern Medicine investigators have discovered a novel signaling pathway activated by interferons, a group of immune system proteins, that suppresses the anti-tumor response of interferons in patients with a particular type of blood cancer, according to findings published in Nature Communications. Targeting this pathway in combination with...
by The Ottawa Hospital A Natural Killer cell (arrow) turns green after stealing a chunk of a green cancer cell. Cancer cells hijack this process to put Natural Killer cells to sleep and evade the immune system. Credit: Hasim et al., Sci. Adv. 8, eabj3286 (2022) Researchers at the Ottawa Hospital and the University of Ottawa...
by South Australian Health and Medical Research Institute (SAHMRI) Graphical abstract. Credit: DOI: 10.15252/embr.202152904 Adelaide researchers have discovered a new method to treat the rare and crippling blood cancer, myelofibrosis, that could have the potential to greatly extend lifespan while also significantly improving quality of life. Myelofibrosis affects 1 in 100,000 Australians and while symptoms...
by University of Birmingham Immune reconstitution following CD20 depletion and vaccine responsiveness. (A) Time between last administration of anti-CD20 B-cell-depleting treatment and vaccine administration (left panel—haemato-oncology patients [red], right panel—rheumatology patients [blue]). (B) Seropositivity following SARS-CoV-2 vaccination with respect to time from last administration of anti-CD20 B-cell depletion. (C) Association between the magnitude of antibody...
Cancer occurs when there is a genetic defect which spreads as cells divide. Modern science has tools to detect those genetic genes and maybe we will be able to fix them some day. Scientists at the University of Birmingham and Queen’s University Belfast have revealed that a defective gene normally found in blood cancers could be...
by The Mount Sinai Hospital Killer T cells surround a cancer cell. Credit: NIH Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma. They also identified potential targeted...
More than half of double vaccinated blood cancer patients have been left with little protection against COVID-19, new research has found. Data from the SOAP-02 trial, published today in a letter to Cancer Cell, examines the level of immune protection following the delayed Pfizer vaccine boost in 159 participants, 128 of whom were cancer patients. Although...
